Join Immix Biopharma for a Virtual Key Opinion Leader (KOL) event to discuss interim trial results from the NEXICART-2 Phase 1/2 U.S. multi-center clinical trial of cell therapy NXC-201 in patients with relapsed/refractory AL Amyloidosis following its 2025 American Society of Clinical Oncology (ASCO) Oral Presentation in Chicago, IL.

The event will feature Heather Landau, MD (Memorial Sloan-Kettering Cancer Center, NEXICART-2 Principal Investigator, ASCO presenter), Shahzad Raza, MD (Cleveland Clinic), and Jeffrey Zonder, MD (Karmanos Cancer Institute), who will discuss their clinical experience with NXC-201 cell therapy and the evolving treatment landscape for relapsed/refractory AL Amyloidosis.

A live question and answer session will follow the discussion.